MedWatch

Novo skeptical about sharing data with rivals

A new tendency in the biotech and pharmaceutical industry – embraced by Lundbeck among others – sees companies sharing research data with competitors in a bid to secure more data for clinical studies. But the Head of Development in Novo Nordisk does not see the purpose of such collaborations.

Foto: Lundbeck/PR

It is becoming increasingly expensive and difficult to find treatments for diseases. As a consequence several pharmaceutical companies have teamed up with competitors and started sharing clinical data, so the total pool of data becomes greater for everyone involved.

That goes for Danish company Lundbeck which is part of the joint research database NEWMEDS, the world’s largest database containing research data on schizophrenic and depressive patients. The database provides Lundbeck the opportunity to use patient data from rival companies such as Swedish-British AstraZeneca and French company Novartis.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Dansk Biotek skifter navn

Den danske brancheorganisation for biotekselskaber, Dansk Biotek, skifter navn til "Danish Bio - Dansk Biotek" for at imødekomme den stigende internationalisering af branchen, fortæller formand.

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier